Evidence map›Paper›PMID 33980590›Full record

ArticleJournal for immunotherapy of cancer2021

Ivan de Kouchkovsky, Li Zhang, Errol J Philip, Francis Wright, Daniel M Kim, Divya Natesan, Daniel Kwon, Hansen Ho, Son Ho, Emily Chan and 11 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Somatic alterations ofFrontiers in oncology · 2023
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Frontiers in immunology · 2022
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 1 institution in 1 country.

Ivan de KouchkovskyMedicine, University of California San Francisco, San Francisco, California, USA.ORCID 0000-0002-3092-3565
Li ZhangMedicine, University of California San Francisco, San Francisco, California, USA.
Errol J PhilipUniversity of California San Francisco School of Medicine, San Francisco, California, USA.
Francis WrightUniversity of California San Francisco School of Medicine, San Francisco, California, USA.
Daniel M KimUniversity of California San Francisco School of Medicine, San Francisco, California, USA.
Divya NatesanMedicine, University of California San Francisco, San Francisco, California, USA.
Daniel KwonMedicine, University of California San Francisco, San Francisco, California, USA.
Hansen HoUniversity of California San Francisco School of Pharmacy, San Francisco, California, USA.
Son HoUniversity of California San Francisco School of Pharmacy, San Francisco, California, USA.
Emily ChanPathology, University of California San Francisco, San Francisco, California, USA.
Sima P PortenUrology, University of California San Francisco, San Francisco, California, USA.
Anthony C WongRadiation Oncology, University of California San Francisco, San Francisco, California, USA.
Arpita DesaiMedicine, University of California San Francisco, San Francisco, California, USA.
Franklin W HuangMedicine, University of California San Francisco, San Francisco, California, USA.
Jonathan ChouMedicine, University of California San Francisco, San Francisco, California, USA.
David Y OhMedicine, University of California San Francisco, San Francisco, California, USA.
Raj S PruthiUrology, University of California San Francisco, San Francisco, California, USA.
Lawrence FongMedicine, University of California San Francisco, San Francisco, California, USA.
Eric J SmallMedicine, University of California San Francisco, San Francisco, California, USA.
Terence W FriedlanderMedicine, University of California San Francisco, San Francisco, California, USA.
Vadim S KoshkinMedicine, University of California San Francisco, San Francisco, California, USA Vadim.Koshkin@ucsf.edu.
University of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmune checkpoint inhibitors (ICI) can achieve durable responses in a subset of patients with locally advanced or metastatic urothelial carcinoma (aUC). The use of tumor genomic profiling in clinical practice may help suggest biomarkers to identify patients most likely to benefit from ICI.

methodsWe undertook a retrospective analysis of patients treated with an ICI for aUC at a large academic medical center. Patient clinical and histopathological variables were collected. Responses to treatment were assessed for all patients with at least one post-baseline scan or clear evidence of clinical progression following treatment start. Genomic profiling information was also collected for patients when available. Associations between patient clinical/genomic characteristics and objective response were assessed by logistic regression; associations between the characteristics and progression-free survival (PFS) and overall survival (OS) were examined by Cox regression. Multivariable analyses were performed to identify independent prognostic factors.

resultsWe identified 119 aUC patients treated with an ICI from December 2014 to January 2020. Genomic profiling was available for 78 patients. Overall response rate to ICI was 29%, and median OS (mOS) was 13.4 months. Favorable performance status at the start of therapy was associated with improved OS (HR 0.46, p=0.025) after accounting for other covariates. Similarly, the presence of a

conclusionsThe presence of a

Indexed as

MutationPromoter Regions, GeneticAgedBiomarkers, TumorCarcinomaDNA Mutational AnalysisFemaleHigh-Throughput Nucleotide SequencingHumansImmune Checkpoint InhibitorsMalePredictive Value of TestsProgression-Free SurvivalRetrospective StudiesRisk AssessmentRisk FactorsBiomarkers, TumorImmune Checkpoint InhibitorsTelomeraseTERT protein, humangenetic markersimmunotherapytumor biomarkersurinary bladder neoplasms

Identifiers

PMID33980590
PMCPMC8118032
OpenAlexW3161584863

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.